About
Pricing
FAQs
Providers
Trials
Blog
Login
Get started
Finding studies
Search
Narrow
Order
Status
Recruiting
Not yet recruiting
Active, not recruiting
Enrolling by invitation
Completed
Terminated
Phase
Early phase 1
Phase 1
Phase 1–2
Phase 2
Phase 2–3
Phase 3
Phase 4
No phase
Who can join
Healthy volunteers too
Searching
1–20 of 26
Not yet recruiting
Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia
This is an open-label, single-institution pilot study of single-agent golidocitinib enrolling up to 24 patients in two cohorts: a) advanced-stage mycosis fungoides/Sézary syndrome…
NCT07682792
·
St Louis, Missouri
Terminated
Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as methotrexate and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping…
NCT00278265
·
Berlin and 6 others
Terminated
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
RATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT00671112
·
Cleveland, Ohio
Recruiting
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
Hematological diseases are disorders of the blood and hematopoietic organs.
NCT07019766
·
Tianjin, Tianjin Municipality
Recruiting
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently…
NCT06530550
·
Tianjin, Tianjin Municipality
Recruiting
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia.
NCT05592015
·
Boston, Massachusetts and 2 others
Completed
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
T Cell Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders are a heterogeneous group of uncommon diseases which may involve a polyclonal or a monoclonal T cell…
NCT00001533
·
Bethesda, Maryland
Terminated
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).
NCT05316116
·
Tampa, Florida
Recruiting
Registry of the German CLL Study Group
Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma…
NCT02863692
·
Dresden, Saxony
Completed
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R)…
NCT05225584
·
Orange, California and 12 others
Completed
Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia
This study will examine the use of the humanized Mik-beta-1 (Hu-Mik-beta1) antibody in patients with T-cell large granular lymphocytic leukemia (T-LGL).
NCT00076180
·
Bethesda, Maryland
Recruiting
National Longitudinal Cohort of Hematological Diseases
Background Hematological diseases are disorders of the blood and hematopoietic organs.
NCT04645199
·
Tianjin, Tianjin Municipality
Completed
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
This study will examine the use of alemtuzumab (Campath) in patients with T cell large granular lymphocytic leukemia (T-LGL).
NCT00345345
·
Bethesda, Maryland
Recruiting
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients…
NCT05475925
·
Birmingham, Alabama and 36 others
Unknown
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.
NCT02742727
·
Suzhou, Jiangsu
Completed
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
NCT05532722
·
Duarte, California and 7 others
Terminated
Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia
Background: * Large granular lymphocyte (LGL) leukemia is a low-grade non-Hodgkin's lymphoma.
NCT00363779
·
Bethesda, Maryland
Completed
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
NCT00019032
·
Bethesda, Maryland
Recruiting
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently…
NCT06716658
·
Tianjin, Tianjin Municipality and 1 other
Completed
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
RATIONALE: Cyclosporine may improve low blood counts caused by hematologic cancer.
NCT00031980
·
Buffalo, New York
Back
1
2
1 / 2
Next
Data from
ClinicalTrials.gov
Terms
